ReviewAnnals of medicine and surgery (2012)2025
Advancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelofibrosis (MF) is a rare and progressive blood disorder marked by fibrosis of the bone marrow, abnormal blood cell production, and often severe anemia. The disease is commonly associated with debilitating symptoms such as fatigue, weakness, and an enlarged spleen. Ojjaara (momelotinib), a selective inhibitor of Janus kinases (JAK1/2), offers a promising treatment option for patients with MF, particularly those suffering from anemia. By targeting the dysregulated JAK-STAT signaling pathway, Ojjaara helps restore normal blood cell production and reduces fibrosis in the bone marrow. Several clinical trials, including the MOMENTUM and SIMPLIFY-1 studies, have highlighted the drug's ability to improve symptoms related to anemia, decrease spleen size, and enhance overall quality of life, with a manageable side effect profile. This review examines the role of momelotinib in treating MF, focusing on its mechanism, clinical benefits, patient selection criteria, monitoring strategies, potential side effects, and findings from key clinical trials. While promising, careful patient management is essential to minimize adverse effects and optimize the therapeutic benefits of momelotinib in MF treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.